Mon February 17 – 10 Stories of The Day!

1 – Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations – Critical Care Medicine (free)

News Release: New guidelines for hepatic failure in the intensive care unit – Wolters Kluwer Health (free)

See also: Executive Summary (free)

2 – 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation – Journal of the American College of Cardiology (free PDF)

See also: Mitral Regurgitation Management Focused Update: Key Points – American College of Cardiology (free)

3 – A Randomized Controlled Trial of Ceftriaxone and Doxycycline, with or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease – Clinical Infectious Diseases (link to abstract – $ for full-text)

4 – Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 – The Lancet (free)

News Release: Chronic kidney disease a ‘global killer in plain sight’ – Institute for Health Metrics and Evaluation (free)

Commentaries: The global burden of chronic kidney disease – The Lancet (free) AND Chronic kidney disease killing millions worldwide – News Medical (free) AND Chronic kidney disease kills more than 1M people annually worldwide – UPI (free)

5 – 65 Trial – The Bottom Line (free) AND The 65 trial: Is 60 the new 65? – PulmCrit (free)

Original Study: Randomized Trial: Comparison of Different Blood Pressure Targets for Vasopressor Therapy in Older Critically Ill Patients with Vasodilatory Hypotension – JAMA (free)

6 – Alex Nowbar’s weekly journal review, 14 February 2020 – The BMJ Opinion (free)

“Alex Nowbar reviews the latest research from the top medical journals.”

7 – FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market Potential risk of cancer outweighs the benefits – U.S. Food & Drug Administration (free)

Source: Lorcaserin (Belviq ) Withdrawn From US Market Due to Cancer Risk – Medscape (free registration required)

Related: FDA Safety Communication: Possible Increased Risk of Cancer with Weight-loss Medicine Lorcaserin (free)

8 – Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis – The American Journal of Gastroenterology (link to abstract – $ for full-text)

Commentary: Fecal Occult Blood Tests Should Not Be Used for Diagnostic Indications – NEJM Journal Watch (free for a limited period)

9 – An electroencephalographic signature predicts antidepressant response in major depression – Nature Biotechnology (link to abstract – $ for full-text)

Commentaries: Neural signature identifies people likely to respond to antidepressant medication – NIH News Releases (free) AND Brain-wave pattern can identify people likely to respond to antidepressant, study finds – Stanford Medicine (free) AND AI, brain scans may alter how doctors treat depression – UT Southwestern Medical Center (free) AND Brain scans could be used to identify who will benefit from antidepressants – Business Insider (free) AND Resting-State EEG Can Predict Sertraline Treatment Outcomes – MPR (free) AND Will That Antidepressant Work For You? The Answer May Lie In Your Brain Waves – NPR (free)

10 – Novel Coronavirus Disease (COVID-19) Latest Articles, Guidelines, News & Perspectives / 17 February 2020 Edition

17 February 2020 Edition – COVID-19/SARS-CoV-2 Latest Articles, Guidelines, News & Perspectives (several free resources)